Vaccination persuasion: Personal stories most likely to influence people toward COVID-19 shots, analytics firm finds

Syringe injection vaccine needle
When it comes to convincing people to get a COVID-19 vaccine, Civis Analytics testing finds personal stories will be the most compelling. (Pixabay)

As coronavirus vaccines edge closer to market, the next question is how pharma companies and public health authorities will convince people to get them.

Civis Analytics decided to test what kind of messages might work. The data firm created five different themed messages and random tested them with 4,000 respondents. They compared the results to the control group in which 73% said they were likely to get a COVID-19 vaccine.

The result? Personal stories proved to be the best motivator for COVID-19 vaccinations. When people saw a mock ad about a real person, in this case a young healthy person who contracted COVID-19 and died, they were 5% more likely than the control group to say yes to a vaccine.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

The worst-performing message? Community protection. When people were shown an ad that emphasized the value of herd immunity and role of vaccines in making communities healthier for everyone, they were 1% less likely to get the vaccine. However, even more concerning was that by Civis’ calculations, there was a 69% probability that the community protection message would create a negative backlash.

RELATED: Want widespread COVID-19 vaccine adoption? Be transparent about clinical data, experts say

The three other messages focused on safety, economic recovery and statistics. Statistical laundry lists about COVID-19 as a leading cause of death in the U.S.—and prolonged symptoms and health problems for those who have recovered—were neutral with most groups. The exception was adults ages 50 to 64; the percentage of people in that group likely to vaccinate rose by 6 percentage points in response to those messages/

The economic recovery and safety messages also came with a 57% and 45% chance chance of sparking backlash, respectively.

However, it was the sizeable potential backlash from the community message that most surprised Civis. That’s because in its previous flu vaccine message tests, community protection has always been the top motivator, said Director of Healthcare Analytics Crystal Son. Son previously worked as an infection control epidemiologist at Memorial Sloan-Kettering Cancer Center.

RELATED: How does AstraZeneca's trial pause affect other COVID-19 vaccines? Analysts weigh in

Why the lack of altruism around COVID-19 vaccines versus flu? While Civis didn’t ask that specific question, Son hypothesized that not only has COVID-19 become widely politicized, but vaccines for it have, too. Flu is a more familiar annual routine vaccination that people feel OK about getting to help others.

A key takeaway from the study is that pharma and public health agencies won’t be able to simply replicate vaccination strategies for other viruses or diseases.

Civis plans to periodically repeat the coronavirus message testing because as Son noted, it’s likely that both the baseline and persuasive message sway will change over time.

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.